Postpartum Hemorrhage Management Devices Market

Postpartum Hemorrhage Management Devices Market Size

The global postpartum hemorrhage management devices market was estimated at USD 958.6 million in 2024. The market is expected to grow from USD 1 billion in 2025 to USD 1.6 billion in 2034, at a CAGR of 5.2% during the forecast period, according to the latest report published by Global Market Insights Inc. The market is driven by rising prevalence of postpartum hemorrhage globally, technological advancements in PPH management devices, a surge in emergency obstetric care demand, and increasing maternal mortality awareness campaigns, among other factors.

Increased funding for maternal health programs, higher incidence of risk factors like uterine atony and anemia, and government initiatives to improve maternal health are among the key factors propelling the product demand. Becton, Dickinson and Company, CooperSurgical, ORGANON, and UTAH MEDICAL PRODUCTS, INC. are among the leading players operating in the market. These players mainly focus on product innovation, adoption of AI-enabled tools, and collaboration with local or regional healthcare providers to enhance their geographical expansion, among others.

The market reached USD 885.2 million in 2023 from USD 718.8 million in 2021. Postpartum hemorrhage (PPH) continues to be one of the primary contributors to maternal mortality globally, specifically in the low-resource setting where timely care is limited. For instance, according to the data reported in a 2022 report by the World Health Organization (WHO), around 14 million women experience PPH each year globally.

As the birth rate and birth complications, such as uterine atony and anemia, are increasing, the needs for effective postpartum management are growing. Hospitals and clinics are using more advanced devices, such as uterine balloon tamponades and surgical devices for emergency care. Furthermore, the efforts of global health organizations to reduce the incidence of maternal death have led to a greater demand for innovative, reliable, and user-friendly PPH management devices in both developed and developing countries

Government agencies, NGOs, and healthcare organizations are all engaged in awareness campaigns to raise attention over the impact of maternal mortality and the significance of timely care during delivery. For example, to raise awareness among women and focus on reducing the patients affected by PPH, the World Health Organization (WHO), in collaboration with various other associations from across the world, launched the Roadmap to Combat Postpartum Hemorrhage between 2023 and 2030. The initiative will focus on better research, advocacy, and implementation of strategies to improve the overall outcome.

In addition to raising awareness of the use of technologies and devices in preventing complications of childbirth, these campaigns create a supportive infrastructure for the manufacturers of these devices to expand their market potential, product reach, and partnerships with health care systems around the world. Further, the growing focus and popularity of technological advancements such as AI-driven predictive analytics and connected platforms, the development of portable devices, and other innovations are anticipated to propel the industry's growth over the analysis period.

Postpartum hemorrhage management devices are medical equipment used to manage excess bleeding after childbirth. These devices are a means to reduce maternal mortality, and they also help improve outcomes in obstetric emergencies.

Postpartum Hemorrhage Management Devices Market Trends

Growing emphasis on training and education programs, focusing on cost-effective solutions for low-resource settings, rising adoption of uterine balloon tamponade devices, and sustainability and eco-friendly device design are among the key trends shaping the market growth in an upward trajectory.

• Healthcare professionals increasingly prefer the uterine balloon tamponade devices for the rapid and effective control of uterine hemorrhage. These devices are used in minimally invasive procedures and have demonstrated clinical effectiveness in obstetric care settings. The safety and efficacy profiles of such products help to foster and expedite widespread adoption around the world.
  
• Additionally, manufacturers are working consistently to develop affordable, user-friendly devices that address the unmet needs of maternal health in the developing countries. These needs are the result of high birth rates and limited health care infrastructure, allowing access to portable PPH products that address the needs in a simplified manner.
  
• Further, companies and governments are investing in labor and delivery training for clinicians to know how to use devices and to be prepared for emergencies effectively. This enhances the adoption of products, thereby reducing the maternal mortality by enabling a better-trained workforce.
  
• Furthermore, there is an increasing focus on reusable or biodegradable components in PPH devices to address public concerns over medical waste and to support global sustainability efforts, which contributes to advanced strategies for product development.
  

Postpartum Hemorrhage Management Devices Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

In 2021, the market was valued at USD 718.8 million and grew to USD 799.8 million in 2022, reaching USD 885.2 million by 2023. Rising investments in maternal health research and training programs for healthcare workers in PPH management are among the key variables contributing to industry growth.

Based on product type, the global postpartum hemorrhage management devices market is segmented into uterine tamponade devices, non-pneumatic anti-shock garments (NASG), and prefilled injection system. The uterine tamponade devices segment held the largest share of 55.2% in 2024, driven by the high incidence of risk factors such as uterine atony and anemia, along with supportive government initiatives aimed at improving maternal health outcomes. The segment is projected to surpass USD 900.2 million by 2034, expanding at a CAGR of 5.5% during the forecast period.

• Uterine tamponade devices are specifically designed to manage significant postpartum hemorrhage by exerting internal pressure directly within the uterus. Tamponade devices, which are mainly balloon devices, can minimize the need for surgical intervention while providing a quick stabilizing solution for patients.
  
• Additionally, due to their safety and efficacy, they are being adopted across different healthcare settings as one of the effective ways to reduce maternal mortality and are easily deployed in obstetric emergencies. They are becoming increasingly utilized in obstetric practices worldwide due to clinical guidelines that recommend tamponade for uncontrolled hemorrhage as a first-line intervention.
  
• The non-pneumatic anti-shock garments (NASG) segment was valued at USD 251.1 million in 2024. The NASG is a low-cost, reusable device that helps to stabilize women who have severe postpartum hemorrhage by applying circumferential pressure to the lower half of the body, thus improving blood flow to the important organs while slowing down the hemorrhage until definitive treatment can be provided.
  
• NASG is especially beneficial in low-resource settings where surgical procedures cannot be initiated immediately. Its portability, affordability, and simplicity make it a key resource in emergency obstetric care in under-resourced rural settings, helping to decrease rates of maternal mortality and morbidity.
  
• Further, prefilled injection systems are anticipated to record robust growth with a CAGR of 4.8% through the analysis timeframe. Prefilled injection systems provide fast and accurate delivery of uterotonic medications such as oxytocin or misoprostol to prevent or treat postpartum hemorrhage.
  
• They are increasingly utilized as the preferred method of uterotonic administration in developed and developing countries due to their proven efficacy, reliability, and ease of use. Prefilled injection systems have numerous advantages that make them essential tools for incorporation into either emergency obstetric kits or maternal health care programs across the globe.
  

Based on patient type, the global postpartum hemorrhage management devices market is segmented into primary PPH, and secondary PPH. The primary PPH segment accounted for a dominating share and was valued at USD 795 million in 2024.

• Primary postpartum hemorrhage (PPH) occurs in the first 24 hours following delivery, and it is the most common and severe type of PPH. Primary PPH is typically due to uterine atony, trauma, or retained placental tissue.
  
• Immediate treatment measures of using uterotonics (medications to contract the uterus), uterine tamponade devices, and surgical actions are necessary in order to minimize maternal mortality. Additionally, hospitals prioritize rapid-response protocols for primary PPH, making this category a key driver for advanced device adoption and emergency obstetric care solutions that are focusing on procedural management of PPH globally.
  
• Further, the secondary PPH segment was valued at USD 163.6 million in 2024. Secondary postpartum hemorrhage, characterized as bleeding after 24 hours and up to 12 weeks after delivery, is generally due to infection, retained products, or abnormal healing at the placental site. Management involves imaging studies for diagnosis and treatment with uterotonics and sometimes surgery.
  
• Secondary PPH is less common than primary but has the potential for complex outcomes that require a long-term follow-up plan for specialized treatment options. The secondary segment critically highlights the need for maternal health strategy and preventive care programs.
  

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the postpartum hemorrhage management devices market is segmented into hospitals, maternity & birthing centers, ambulatory surgical centers, and other end users. The hospitals segment accounted for the leading market share of 65.9% in 2024 as it records high patient footfall including both public and private hospital settings.

• Hospitals account for the largest end-use category for PPH management devices because they provide care for emergency obstetric cases and multidisciplinary maternal care.
  
• They have access to advanced devices, staff awareness and training, and established guidelines for severe hemorrhage management.
  
• In addition, hospitals are also the major sites for adoption of the devices, clinical trials, and training programs, making them important for market expansion.
  
• Additionally, the maternity and birthing centers segment was valued at USD 178.4 million in 2024. Maternity and birthing centers prioritize individualized experiences for childbirth but do not generally offer the ability to perform on-demand surgery.
  
• Various facilities have started adoption of portable, easy-to-use PPH devices with the intent of providing effective control during emergency and complications.
  
• On the other hand, ambulatory surgical centers offer outpatient surgeries and minor obstetric procedures that need efficient and compact PPH management devices. Their use promotes the demand for a cost-effective solution in a quick recovery setting.
  
• Further, ASCs support devices that are user-friendly and easy to maintain, while offering patient safety with minimal complexity to the operation.
  

Looking for region specific data?

Download Free PDF

• The major market for PPH management devices is North America due to improved healthcare systems and high awareness regarding maternal health. Uterine tamponade devices and prefilled injection systems are widely utilized in hospitals and birthing centers in standard obstetric protocols. Growing governmental support for accessibility and insurance coverage for procedural costs promotes increased accessibility.
  
• Additionally, there are training or education programs for clinicians, preventative emergency protocols, and strict hospital protocols, which all facilitate timely interventions that have reduced maternal mortality.
  
• Further, growing demand for minimally invasive solutions and integration of digital health platforms continues to shape the market, making North America a hub for innovation and adoption.
  

The U.S. postpartum hemorrhage management devices market was valued at USD 252.4 million and USD 279.2 million in 2021 and 2022, respectively. In 2024 the market size was valued at USD 330.8 million from USD 307.3 million in 2023. The high prevalence of postpartum hemorrhage in the country is projected to fuel the market growth.

• The U.S. is the leading country in terms of adoption of PPH devices due to its strong regulatory framework, established hospital network, and high level of awareness of maternal safety. Federal programs and private investment in maternal health and maternal safety are improving access to PPH devices and encouraging innovation. For instance, in August 2024, the U.S. Department of Health and Human Services (HHS) announced spending USD 558 million to improve maternal health. A significant percentage of this amount is dedicated to supporting pregnant and new moms and children through voluntary home visiting programs.
  
• The U.S. is observing rapid adoption of AI-based monitoring devices and telehealth solutions that enhance early detection and intervention.
  
• Focused on diminishing maternal mortality and improving maternal health outcomes, the U.S. market has high potential owing to substantial R&D efforts and engagements between manufacturers and healthcare entities.
  

Europe Postpartum Hemorrhage Management Devices Market

Europe accounted for a significant share of the market and was valued at USD 274 million in 2024.

• There is a stable PPH management device growth trend in Europe, benefiting from well-established healthcare systems and government-supported maternal health systems. Countries focus on standardized guidelines for obstetric emergencies that help drive the use of uterine tamponade devices and NASG in hospitals and birthing centers.
  
• Sustainability initiatives are influencing the design of products, and in particular, a shift is being made to reusable and sustainable products. New technologies such as digital monitoring and predictive analytics have started to emerge in the developed markets.
  
• Further, education through training programs for clinicians and other targeted educational programs to increase awareness helps to further facilitate and drive adoption. Through a focus on patient safety and advances in innovation in PPH, Europe is positioned as a key region in the growth of the global market.
  

Germany held significant share of the European market, showcasing strong growth potential.

• Germany is among the developed markets for PPH management devices in Europe, owing to the country's high-quality healthcare systems and regulatory standards. Hospitals utilize the balloon and vacuum-induced tamponade devices along with prefilled injection systems for emergency obstetric care within Germany.
  
• There is a growing focus on training clinicians to follow international safety protocols for managing maternal complications. In addition, the country is witnessing a rapid development of advanced technologies, such as artificial intelligence for monitoring and minimally invasive devices.
  
• Germany has also embraced sustainability and new innovations in maternal health solutions with reusable devices. With government initiatives and insurance coverage to support access, it is aiding the overall market and adoption, which is pushing the country as one of the premier markets in Europe for maternal health solutions.
  

Asia Pacific Postpartum Hemorrhage Management Devices Market

The Asia Pacific market accounted for a substantial share in the market and was valued at USD 235.2 million in 2024.

• There is rapid growth observed in PPH management devices in the Asia Pacific region due to high birth rates and increasing investments in healthcare. To address the issues of maternal mortality, emerging economies are adopting low-cost, innovative solutions such as NASG (Non-pneumatic Antishock Garment) and low-cost portable uterine tamponade devices.
  
• Various regional governments are supporting awareness campaigns and building healthcare infrastructure, and their efforts are providing an opportunity for manufacturers to enter the region. In addition, advances in technology have supported efforts related to digital monitoring and telemedicine in urban communities.
  
• Further, while the regional healthcare system is complex and diverse, it remains the region of high growth potential for innovative and scalable solutions. 
  

China postpartum hemorrhage management devices market is estimated to grow with a robust CAGR, in the Asia Pacific market.

• China's PPH management device market is rapidly expanding due to governmental efforts to improve maternal health and decrease mortality. Hospitals and maternity centers are increasingly utilizing uterine tamponade devices and prefilled injections as routine practice. It is also investing in healthcare infrastructure and clinician training, improving access to devices.
  
• Additionally, emerging technologies, such as artificial intelligence-enabled monitoring and telehealth platforms, are becoming more commonplace in urban hospitals.
  
• Increased awareness, along with affordability initiatives, is continuously supporting uptake in the marketplace and pushing the country as one of the largest drivers in the Asia Pacific overall growth and innovation in maternal health.
  

Latin America Postpartum Hemorrhage Management Devices Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.

• A high maternal mortality rate in Brazil propels the need for efficient management devices for PPH. Government programs and international initiatives strive to enhance access to healthcare services and emergency obstetric services.
  
• Campaigns to raise awareness, training programs for clinicians, and product affordability, which remains a focus for all manufacturers, ensure healthcare services are well-supported in managing PPH.
  
• Additionally, emerging technology continues to roll out to the market, particularly in urban settings that include portable devices or telehealth technologies. Both the increased investment in healthcare and the prioritization of maternal safety indicate a substantial opportunity for device manufacturers seeking to enter or expand in the Latin American market.
  

Middle East and Africa Postpartum Hemorrhage Management Devices Market

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2024.

• Saudi Arabia’s PPH management device market is expanding due to government-led healthcare modernization and maternal health initiatives. The country is investing in clinician training and adopting international safety standards, improving emergency obstetric care.
  
• Technological integration, including digital monitoring and telehealth platforms, is gaining momentum in urban hospitals. Rising awareness and healthcare infrastructure development position Saudi Arabia as a key Middle Eastern market, offering strong growth potential for manufacturers focused on innovative maternal health solutions.
  

Postpartum Hemorrhage Management Devices Market Share

The Postpartum Hemorrhage (PPH) management devices market competitive landscape consists of a mix of global leaders and niche players focused on maternal health solutions. The key players in the PPH Management Devices Market, such as Becton, Dickinson and Company (BD), CooperSurgical, Organon, and Utah Medical Products, have established themselves through strong product portfolios, distribution networks, and ongoing contributions to product innovation in uterine balloon tamponade and surgical devices. In addition, these companies are also involved in partnerships with hospitals and other health care systems to facilitate solutions uptake and also improve the overall brand positioning in the industry.

The competitive environment is moderately consolidated, and high barriers to entry exist due to the complex nature of regulatory compliance and clinical validation. Price sensitivity in emerging markets, the need for sustainability, and ease of use of fuel product development opportunities. Overall, competition is driven by solutions efficacy, affordability, and potential market reach, while there is a growing focus on partnerships with organizations and clinician-driven education of the products being used to help manage maternal health and outcomes.

Postpartum Hemorrhage Management Devices Market Companies

A few of the prominent players operating in the global postpartum hemorrhage management devices industry include:

• 3rd Stone Design
• Becton, Dickinson and Company
• CELOX MEDICAL
• CooperSurgical
• MedGyn
• ORGANON
• PREGNA INTERNATIONAL
• SINAPI
• STERIMED
• UTAH MEDICAL PRODUCTS, INC.
• ZOEX NIASG
  
• Becton, Dickinson and Company

Becton, Dickinson and Company held the leading share in the market with around 18% share in 2024. BD focuses on expanding its maternal health portfolio through advanced PPH management devices, leveraging global distribution networks, and investing in R&D for minimally invasive solutions. The company emphasizes strategic partnerships and training programs to strengthen adoption in emerging markets.

• CooperSurgical

Targets growth via product innovation in obstetric care and acquisitions to broaden its maternal health offerings. The company prioritizes clinician education, integrated solutions for labor management, and geographic expansion into high-birth-rate regions to enhance market penetration.

• UTAH MEDICAL PRODUCTS, INC.

It focuses on a niche-focused strategy emphasizing high-quality, specialized devices for obstetric emergencies. The company leverages strong relationships with hospitals, continuous product refinement, and compliance with global standards to maintain trust and expand in developed and emerging regions.

Postpartum Hemorrhage Management Devices Industry News:

• In September 2024, Organon Canada, a subsidiary of Organon, announced the availability of the JADA System, a medical device intended to control and treat postpartum hemorrhage (PPH), in Canada. This development has expanded the company's geographical presence and may enhance its business prospects.
  
• In February 2024, Baymatob, an Australian medtech startup, received funding from the Medical Research Future Fund (MRFF) as part of the ANDHealth+ digital health commercialization program. The company developed Oli PPH, the first AI-guided product designed to identify women at risk of developing postpartum hemorrhage (PPH) before they give birth. This program supports Australian startups incorporating artificial intelligence (AI) and machine learning in healthcare.
  
• In September 2023, Medtrade Products Ltd. announced that it had entered into an exclusive agreement with KEBOMED Europe AG, a leading European supplier of medical equipment, to distribute the CELOX PPH Uterine Hemostatic Tamponade across France and the UK. This development expanded the company's regional presence and aligns with its plans of global product reach.
  

The global postpartum hemorrhage management devices market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Uterine tamponade devices
  • Balloon tamponade 
  • Vacuum-induced devices    
• Non-pneumatic anti-shock garments (NASG)
• Prefilled injection system

Market, By Patient Type

• Primary PPH
• Secondary PPH

Market, By End Use

• Hospitals
• Maternity & birthing centers
• Ambulatory surgical centers
• Other End Use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE